{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+care+systemic+therapy&page=2",
    "query": {
      "intervention": "Standard of care systemic therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 240,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+care+systemic+therapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+care+systemic+therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T23:57:14.876Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02633163",
      "title": "Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Low Dose Mesenchymal Stem Cells (MSCs)",
          "type": "DRUG"
        },
        {
          "name": "High Dose Mesenchymal Stem Cells (MSCs)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 81,
      "start_date": "2018-11-18",
      "completion_date": "2026-02-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633163"
    },
    {
      "nct_id": "NCT06686771",
      "title": "Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "SBRT",
          "type": "RADIATION"
        },
        {
          "name": "First or second-line standard of care therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Canadian Cancer Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2025-12-16",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 71,
      "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 55 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Grand Junction",
          "state": "Colorado"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06686771"
    },
    {
      "nct_id": "NCT03035890",
      "title": "Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Immuno-Therapeutic Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "West Virginia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2017-01-23",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2025-04-01",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03035890"
    },
    {
      "nct_id": "NCT05403723",
      "title": "Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extensive-stage Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab 50 MG/1 ML Intravenous Solution",
          "type": "DRUG"
        },
        {
          "name": "Etoposide Injection",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiotherapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2027-01-30",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05403723"
    },
    {
      "nct_id": "NCT00936910",
      "title": "Antifungal Locks to Treat Fungal-related Central Line Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Central Line Fungal Infections"
      ],
      "interventions": [
        {
          "name": "amphotericin B liposomal (Ambisome)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bill McGhee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "30 Days to 21 Years"
      },
      "enrollment_count": 13,
      "start_date": "2006-09",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2017-10-10",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00936910"
    },
    {
      "nct_id": "NCT04700124",
      "title": "Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Enfortumab vedotin (EV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RC + PLND",
          "type": "PROCEDURE"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 808,
      "start_date": "2021-04-21",
      "completion_date": "2028-05-18",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04700124"
    },
    {
      "nct_id": "NCT03684980",
      "title": "LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Glucarpidase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2018-11-14",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Basking Ridge, New Jersey + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03684980"
    },
    {
      "nct_id": "NCT05893888",
      "title": "A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Oral Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PRV211 (Intraoperative Cisplatin System)",
          "type": "DRUG"
        },
        {
          "name": "PRV111 (Cisplatin Transmucosal System)",
          "type": "DRUG"
        },
        {
          "name": "PRV131 (Cisplatin Intratumoral Injectable)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Privo Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-11-07",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Miami, Florida • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05893888"
    },
    {
      "nct_id": "NCT06764095",
      "title": "Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Renal Pelvis and Ureter Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Local Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Ureterectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2025-01-08",
      "completion_date": "2032-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06764095"
    },
    {
      "nct_id": "NCT01098981",
      "title": "Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Transcranial ultrasound as an adjunctive therapy to tPA",
          "type": "DEVICE"
        },
        {
          "name": "Standard of care tPA therapy for acute ischemic stroke",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Cerevast Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 675,
      "start_date": "2013-05",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-10-04T23:57:14.876Z",
      "location_count": 1,
      "location_summary": "Redmond, Washington",
      "locations": [
        {
          "city": "Redmond",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01098981"
    }
  ]
}